The place of lithium salts in psychiatric practice 50 years on

Current Opinion in Psychiatry

Volumn 14, Issue 1, 2001, Pages 57-63

  Watson, Stuart ^a   Young, Allan Hunter ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CLOZAPINE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; LAMOTRIGINE; LITHIUM SALT; MARCKS PROTEIN; N ACETYLASPARTIC ACID; OLANZAPINE; PAROXETINE; PHOSPHATIDYLINOSITIDE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P53; RISPERIDONE; SEROTONIN 2A RECEPTOR;

APOPTOSIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; ENZYME REGULATION; HUMAN; MANIA; NEUROPROTECTION; PREGNANCY; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; TUMOR SUPPRESSOR GENE;

EID: 0034985585     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200101000-00010     Document Type: Review

References (99)

1. Lithium perspectives
2. Lithium salts in the treatment of psychotic excitement
3. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe
4. Neurobiology of lithium: An update
5. Neural and developmental actions of lithium: A unifying hypothesis
6. Lithium and valproate have common effects on the Pl-cycle in animals and patients: Magnetic resonance spectroscopy studies
7. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness
8. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: A preliminary study
9. Ziskind-somerfeld research award. Protein kinase C signalling in the brain
10. Low-dose lithium augmentation of divalproex in geriatric mania
11. Regulation of neuroplasticity and MARKS (myristoylated alanine-rich C kinase substrate) expression: A neurobiology for the action of lithium in the brain
12. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania
13. Neuroimaging studies of mood disorders
14. MRI-based measurements of temporal lobe and ventricular structures in patients with bipolar I and bipolar II disorders
15. Quantitative EEG, cognitive performance and MRI abnormalities in young bipolar subjects
16. Subgenual prefrontal codex abnormalities in mood disorders
17. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
18. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
19. Neurogenesis in the adult human hippocampus
20. Neurogenesis in the neocortex of adult primates
21. Signaling: Cellular insights into the pathophysiology of bipolar disorder
22. A molecular mechanism for the effect of lithium on development
23. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase·3
24. Lithium therapy and signal transduction
25. Glycogen synthase kinase·3 beta facilitates staurosporine- and heat shock-induced apoptosis - Protection by lithium
26. Modulation of transcription factor activation by lithium
27. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked?
28. Bcl-2 promotes regeneration of severed axons in mammalian CNS
29. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS
30. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression
31. Lithium as a neuroprotective drug in-vivo and in-vitro: Mechanisms and implications
32. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons
33. Chronic lithium treatment increases brain-derived neurotrophic factor expression in rat hippocampus and cerebellum
34. The role of p53 in neuronal cell death
35. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells
36. Lithium therapy increases grey matter volume
37. Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects?
38. Enhancement of hippocampal neurogenesis by lithium
39. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats
40. Lithium carbonate in Huntington's disease
41. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia
42. Suicide and bipolar disorder
43. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it
44. Lithium therapy and suicide risk
45. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders
46. Reduced suicidality during lithium treatment
47. Anticonvulsant therapy and suicide risk in affective disorders
48. The biology of impulsivity and suicidality
49. Suicidal behavior in bipolar mood disorder: Clinical characteristics of attempters and non attempters
50. Neurochemistry of suicide
51. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder
52. 2A receptor polymorphism and suicidal behaviour
53. Platelet serotonin studies in affective disorders: Evidence for a serotonergic abnormality
54. Effect of lithium carbonate on the enhancement of serotonin 2A receptor elicited by dexamethasone
55. The current status of the platelet 5-HT(2A) receptor in depression
56. Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium
57. Lithium treatment of acute manic disorder
58. Neuroleptics in acute mania: A pharmocoepidemiological study
59. Treatment of manic episodes in Scandinavia: The use of neuroleptic drugs in a clinical routine setting
60. Importance of psychiatric diagnosis in prediction of clinical drug effects
61. Safety and efficacy of risperidone vs placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder
62. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group
63. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
64. Olanzapine compared to lithium in mania: A double-blind randomized controlled trial
65. The systematic treatment enhancement program for bipolar disorder
66. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder
67. Lamotrigine and clozapine for bipolar disorder
68. Clozapine in the treatment of refractory psychotic mania
69. Quetiapine for treatment-resistant mania
70. The use of quetiapine for treatment-resistant bipolar disorder: A case series
71. A three week, double blind, randomised trial of ziprasidone in the acute treatment of mania
72. Lamotrigine compared with lithium in mania: A double-blind randomized controlled trial
73. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group
74. Outcome of lithium prophylaxis: A prospective follow-up of affective disorder patients assigned to high and low serum lithium levels
75. Lithium and recurrence in a long-term follow-up of bipolar affective disorder
76. Maintenance treatment in bipolar disorder
77. Lithium and carbamazepine in bipolar disorder
78. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder
79. Lithium in the prophylactic treatment of affective disorders
80. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison
81. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group
82. Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency
83. Outcome in the pharmacologic treatment of bipolar disorder
84. 2-years outcome in bipolar disorder patients beginning prophylactic treatment
85. The prophylactic efficacy of lithium-transient or persistent?
86. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance
87. Mood stabilizers in the prevention of recurrent affective disorders: A meta-analysis
88. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: A randomized, double-blind, controlled trial
89. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination
90. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression
91. Bipolar depression: Pharmacotherapy and related therapeutic strategies
92. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to as initial mood stabilizer for treatment of patients with bipolar depression
93. A double blind placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression
94. Recent clinical research in bipolar depression
95. Treatment of bipolar depression, a review of the literature
96. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies
97. The efficacy of mood stabilizers in the prevention of recurrent unipolar depression
98. The Expert consensus guideline series: Medication treatment of bipolar disorder 2000